Evidence map›Paper›PMID 43011003›Full record

ReviewJournal of diabetes and metabolic disorders2026

Endocrine life after breast cancer: navigating hormonal challenges from treatment to survivorship.

Mohsen G Soroush, Sana Badamchizadeh, Maedeh Sarvari, Pouya Mehran, Sepideh Alavi-Moghadam, Hamid Reza Aghayan, Mostafa Rezaei-Tavirani, Rasta Arjmand, Sara Keshtkari, Babak Arjmand

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohsen G SoroushRheumatology Department, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Sana BadamchizadehCancer Supportive and Palliative Care Research Center, Iranian Cancer Control Charity instituation (MACSA), , Tehran, Iran.ORCID 0009-0003-8584-851X
Maedeh SarvariEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Pouya MehranCell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Sepideh Alavi-MoghadamCell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-4488-9131
Hamid Reza AghayanCell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-8348-1449
Mostafa Rezaei-TaviraniProteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-1767-7475
Rasta ArjmandSchool of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Sara KeshtkariDepartment of Internal Medicine, AJA University of Medical Sciences, Tehran, Iran.
Babak ArjmandHematologic Malignancies Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-5001-5006

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose of review: This review examines the hormonal challenges that breast cancer survivors encounter, with a particular emphasis on endocrine treatment side effects and how they affect survivorship. Recent findings: Endocrine therapy is the mainstay for estrogen receptor-positive breast cancer, and improvements in detection and treatment have improved survival. Premature menopause, bone loss, metabolic dysfunction, and sexual health problems are examples of treatment-induced side effects that have been shown to impair adherence and quality of life. Summary: Long-term endocrine problems that profoundly impact health and well-being are experienced by breast cancer survivors. Pharmacological, non-hormonal, and lifestyle interventions are among the multidisciplinary approaches necessary for effective management, aiming to increase adherence, reduce recurrence, and improve overall survivorship outcomes.

Indexed as

Breast Neoplasms/therapyEndocrine Therapy / adverse effectsEstrogen DeprivationQuality of LifeTreatment Adherence and Compliance

Identifiers

PMID43011003
PMCPMC13748199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.